D019009Chemicals & DrugsD08.811.913.696.620.682.725.400.050D12.776.543.750.630.124D12.776.543.750.705.852.150.100D12.776.543.750.750.400.200.170D12.776.624.664.700.18342790.964841Proto-Oncogene Proteins c-kitprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson28734009Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chlopik A, Tell-Marti G, Paral KM, Shalin SC, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MPThe British journal of dermatologyKIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol. 2017 Nov; 177(5):1376-1384.Br J Dermatol2017-11-05T00:00:002017KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas.1.116650.013437942research area of0.6419080.044983262subject area forBen May DepartmentMedicinePathologyUniversity of ChicagoEzraCohenEzra Cohen41.78927490000000-87.601250000000001350Cohen, EzraASSOCIATE PROFESSORChristopherShea1HFhDqA1DO/RmHllZ0mg9mHvChristopher Shea41.78927490000000-87.601250000000001566Shea, ChristopherClinical ProfessorRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, ProfessorRichardJonesRichard B. Jones41.78927490000000-87.601250000000002031Jones, RichardAssistant Professortrue1Assistant ProfessorAssistant Professortrue1ASSOCIATE PROFESSORASSOCIATE PROFESSORtrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Clinical ProfessorClinical Professortrue1ProfessorProfessor25609545Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele ADCancer imaging : the official publication of the International Cancer Imaging SocietyMetabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.Cancer Imaging2014-11-12T00:00:002014Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.25043300Yun EJ, Baek ST, Xie D, Tseng SF, Dobin T, Hernandez E, Zhou J, Zhang L, Yang J, Sun H, Xiao G, He D, Kittler R, Hsieh JTOncogeneDAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1. Oncogene. 2015 May 21; 34(21):2741-52.Oncogene2014-07-21T00:00:002014DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1.26598548Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EEAnnals of oncology : official journal of the European Society for Medical OncologyPhase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.Ann Oncol2015-11-23T00:00:002015Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.Medicine-DermatologyDanielArberDaniel Arber0.000000000000000.000000000000003406Arber, DanielProfessor25780004Chisholm KM, Merker JD, Gotlib JR, Gitana G, Lefterova M, Zehnder JL, George TI, Arber DA, Ohgami RSAmerican journal of clinical pathologyMast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am J Clin Pathol. 2015 Apr; 143(4):527-34.Am J Clin Pathol2015-04-01T00:00:002015Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry.